RESUMO
OBJECTIVE: The aim: To evaluate the hemodynamic and echocardiographic parameters, the level of adiponectin and IL-6 in such patients under the influence of therapy with sartans (telmisartan or olmesartan) and atorvastatin 12 weeks later. PATIENTS AND METHODS: Materials and methods: Fifty patients with arterial hypertension of II stage and 2 level, who underwent elective in-patient treatment were examined. During the next 12 weeks, they took olmesartan (1st group) or telmisartan (2nd group) in combination with atorvastatin. RESULTS: Results: The combined use of olmesartan or telmisartan in with atorvastatin for 12 weeks had a resulted in a significant decrease in systolic and diastolic blood pressure, heart rate and myocardial mass. After treatment with olmesartan in combination with atorvastatin, the adiponectin content in the blood increased by 41.6% (p <0.05). In the group of patients who receiving telmisartan, an increase adiponectin level was noted in 80.0% of patients and a had shown a significantly higher increase in adiponectin levels, namely for 59.4% after treatment (p <0.01). The level of IL-6 has significantly decreased, both with the administration of olmesartan (2.7 times) and telmisartan (2.6 times) (p<0.01). CONCLUSION: Conclusions: Telmisartan, in comparison with olmesartan, significantly reduces the size of the left ventricular and left atrium myocardium, and decreased left ventricular mass index. Telmisartan improves the cardio-metabolic profile of obese and hypertensive patients by increase of adiponectin concentrations and decrease of IL-6 levels.